SVB Leerink Comments on H. Lundbeck A/S’s Q1 2022 Earnings (OTCMKTS:HLUYY)

H. Lundbeck A/S (OTCMKTS:HLUYY – Get Rating) – Equities researchers at SVB Leerink upped their Q1 2022 EPS estimates for H. Lundbeck A/S in a research note issued on Thursday, April 21st. SVB Leerink analyst M. Goodman now forecasts that the company will earn $0.58 per share for the quarter, up from their previous estimate of $0.51. SVB Leerink also issued estimates for H. Lundbeck A/S’s Q2 2022 earnings at $0.67 EPS, Q3 2022 earnings at $0.58 EPS and Q4 2022 earnings at $0.33 EPS.

Other equities research analysts also recently issued reports about the company. Barclays reduced their target price on H. Lundbeck A/S from 200.00 to 190.00 in a report on Tuesday, February 22nd. JPMorgan Chase & Co. dropped their price target on H. Lundbeck A/S from 250.00 to 200.00 in a research report on Tuesday, January 4th. Credit Suisse Group dropped their price target on H. Lundbeck A/S from 175.00 to 163.00 in a research report on Thursday, February 10th. Finally, Zacks Investment Research raised H. Lundbeck A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, April 12th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, H. Lundbeck A/S has an average rating of “Hold” and an average target price of $122.93.

Shares of OTCMKTS HLUYY opened at $23.74 on Friday. H. Lundbeck A/S has a 12 month low of $21.99 and a 12 month high of $33.16. The company has a market cap of $4.73 billion, a price-to-earnings ratio of 14.48 and a beta of 0.64. The business has a fifty day simple moving average of $23.79 and a 200-day simple moving average of $25.07.

The firm also recently declared a dividend, which was paid on Tuesday, April 5th. Investors of record on Friday, March 25th were given a dividend of $0.2044 per share. This represents a yield of 0.85%. The ex-dividend date of this dividend was Thursday, March 24th. H. Lundbeck A/S’s payout ratio is 12.20%.

H. Lundbeck A/S Company Profile (Get Rating)

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia.

Further Reading